Pulmonary Hypertension Associated With Left Heart Disease: Challenges, Emerging Strategies, and Future Directions

Area of Science:

• Cardiology
• Pulmonology
• Clinical Trials

Background:

• Pulmonary hypertension (PH) linked to left heart disease (LHD) is the most common PH type, posing significant health risks.
• Diagnosing PH-LHD is complex due to similar symptoms, inaccurate echocardiograms, and the need for invasive tests.
• Existing pulmonary arterial hypertension drugs are ineffective and potentially harmful for PH-LHD patients.

Purpose of the Study:

• To review current knowledge on PH-LHD.
• To highlight novel pharmacologic and invasive treatments under investigation.
• To discuss challenges in clinical trial design and propose a framework for future research.

Main Methods:

• Literature review of current knowledge on PH-LHD.
• Summary of emerging pharmacologic agents (e.g., sotatercept, relaxin analogues, levosimendan).
• Overview of investigational device-based strategies (e.g., pulmonary artery denervation, transcatheter atrial shunts).

Main Results:

• No approved pharmacologic or interventional therapies specifically for PH-LHD exist beyond treating LHD.
• Several promising agents and device strategies are in early investigation stages.
• Clinical trial progress is impeded by recruitment challenges, patient variability, and outcome measurement issues.

Conclusions:

• PH-LHD requires specialized diagnostic and therapeutic approaches.
• Emerging therapies show potential but need rigorous clinical validation.
• Overcoming trial design barriers is crucial for advancing PH-LHD treatment.